RxFX - A Mobile Application to Prevent Misuse of Prescription Drugs

RxFX - 防止滥用处方药的移动应用程序

基本信息

  • 批准号:
    8253541
  • 负责人:
  • 金额:
    $ 20.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2013-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The availability of prescription medications, coupled with misconceptions about their safety and addictive potential, has contributed to the surge in prescription (primarily opioid painkillers) misuse, abuse, dependence, and overdose, and to the death of college students. Thus, it is increasingly important for college students misusing prescription opioids (PO) to discontinue use and for those using PO for legitimate medical reasons to use only as medically prescribed. Few resources are available to help college students understand the risks of PO and motivate and support their attempts to reduce or eliminate PO misuse. In order to provide coping skills, healthy alternatives, education and activities to alter attitudes and behaviors toward PO misuse use by students, Eyes of the World Media Group (EOW), in collaboration with UCLA Integrated Substance Abuse Programs (ISAP), proposes to develop Rx Effects (RxFX), an interactive mobile phone application that fulfills the need for a PO intervention program designed for college students. The project directly benefits public health by creating a novel commercial product that communicates and disseminates drug prevention and health promotion information in an engaging way through college students' technology of choice, the mobile phone. RxFX will provide information and activities to students to change their attitudes and behavioral intentions regarding the risks of PO misuse/abuse and provide healthy alternatives to PO use. The long-term goal of RxFX is to develop and evaluate an effective, low-cost, mobile application that can be easily disseminated widely to college students. This Phase I application proposes to develop the content, initial structure and evaluate the feasibility of the mobile application's potential to educate students about and deter the misuse of PO. The completed RxFX prototype will integrate the following features: goal setting, identification of motivators, educational games, coaching on coping skills, guided media creation to encourage self expression, and integration with web 2.0 social media resources (e.g. Facebook). The aim is to lay the foundation for a customizable, mobile application that provides PO users with individualized strategies to limit or discontinue use by tailoring content to individual circumstances and motivations for PO use. An expert advisory group consisting of addiction experts, drug prevention experts, campus health, student life, and other student affairs professionals will inform content development. In Phase 1, the content and structure for the mobile application will be assessed for feasibility by measuring 1) knowledge, 2) attitudes about risk, 3) readiness for behavioral change, 4) perceived utility, and 5) satisfaction with the product by students using PO (N=40). Evaluative data will be collected via focus groups, rating scales, and pre/post rating questionnaires to inform a pilot effectiveness trial to be implemented during Phase II. PUBLIC HEALTH RELEVANCE: The development of an advanced mobile phone application to prevent misuse of prescription drugs by college students will help curb the increasing trend of misuse and reduce the morbidity and mortality associated with prescription opioid addiction. The content development and feasibility testing of such a resource will assess the potential of several features and aid in laying the foundation for a prevention and intervention program informed by college students' preferences and based on best-evidenced practices. Engaging youth through the proposed mobile-based approach has the potential to 1) deliver personalized prescription opiate misuse prevention/intervention to college students during their everyday lives and in natural settings, and 2) offer college students an array of health promotion support tools in a cost-effective and entertaining manner.
描述(由申请人提供):处方药的可用性,加上对其安全性和成瘾潜力的误解,导致处方药(主要是阿片类止痛药)误用,滥用,依赖和过量的激增,以及大学生的死亡。因此,对于滥用处方阿片类药物(PO)的大学生来说,停止使用和那些出于合法医疗原因使用PO的人来说,只按照医疗规定使用越来越重要。很少有资源可以帮助大学生了解PO的风险,并激励和支持他们减少或消除PO滥用的尝试。为了提供应对技能,健康的替代品,教育和活动,以改变态度和行为对PO滥用使用的学生,世界媒体集团(EOW)的眼睛,在与加州大学洛杉矶分校综合药物滥用计划(ISAP)合作,建议开发Rx效果(RxFX),一个互动的移动的手机应用程序,满足需要的PO干预计划专为大学生。该项目创造了一种新的商业产品,通过大学生选择的技术-移动的电话,以吸引人的方式传播预防吸毒和促进健康的信息,从而直接造福于公共卫生。RxFX将为学生提供信息和活动,以改变他们对PO误用/滥用风险的态度和行为意图,并提供健康的PO使用替代品。RxFX的长期目标是开发和评估一个有效的,低成本的,移动的应用程序,可以很容易地广泛传播给大学生。本阶段I应用程序建议开发内容、初始结构并评估移动的应用程序教育学生并阻止PO滥用的潜力的可行性。完成的RxFX原型将整合以下功能:目标设定,激励因素识别,教育游戏,应对技能辅导,引导媒体创作以鼓励自我表达,以及与Web 2.0社交媒体资源(例如Facebook)的整合。其目的是为可定制的移动的应用程序奠定基础,该应用程序为PO用户提供个性化策略,通过根据PO使用的个人情况和动机定制内容来限制或停止使用。由成瘾专家,药物预防专家,校园健康,学生生活和其他学生事务专业人员组成的专家咨询小组将为内容开发提供信息。在第1阶段,将通过测量1)知识,2)对风险的态度,3)行为改变的准备,4)感知效用,5)使用PO的学生对产品的满意度,评估移动的应用程序的内容和结构的可行性(N=40)。将通过焦点小组、评级量表和前/后评级问卷收集评价数据,以告知将在II期实施的试点有效性试验。 公共卫生关系:开发一种先进的移动的手机应用程序来防止大学生滥用处方药,将有助于遏制滥用的增长趋势,并降低与处方阿片类药物成瘾相关的发病率和死亡率。这种资源的内容开发和可行性测试将评估几个功能的潜力,并有助于根据大学生的偏好和最佳实践为预防和干预方案奠定基础。通过拟议的基于移动的方法吸引青年有可能1)在日常生活和自然环境中为大学生提供个性化的处方阿片类药物滥用预防/干预,2)以具有成本效益和娱乐性的方式为大学生提供一系列健康促进支持工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Emily Meyers其他文献

Emily Meyers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Emily Meyers', 18)}}的其他基金

iDecide: A Mobile Decision Support Tool Used for Adjuvant Therapy
iDecide:用于辅助治疗的移动决策支持工具
  • 批准号:
    8395179
  • 财政年份:
    2012
  • 资助金额:
    $ 20.3万
  • 项目类别:
A Web-Based Multimedia Resource for Prescription Opiate Treatment
用于处方阿片治疗的基于网络的多媒体资源
  • 批准号:
    8059759
  • 财政年份:
    2011
  • 资助金额:
    $ 20.3万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 20.3万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 20.3万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 20.3万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 20.3万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 20.3万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 20.3万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 20.3万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 20.3万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 20.3万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 20.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了